news
Anti-PD-1 antibody gains EU approval for oesophageal cancer
Approval of BeiGene’s TEVIMBRA® (tislelizumab) in EU follows an agreement with Novartis to regain global rights of the antibody treatment.
List view / Grid view
oesophageal cancer
article
France’s ATU reform: early access remains possible, but not all diseases are equal
When France's ATU reform was implemented, some viewed it as restrictive. Here, Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases.
news
Opdivo® approved in Europe to treat a range of cancers
Opdivo® (nivolumab) has been approved by the European Commission for gastric, gastroesophageal junction (GEJ), or oesophageal adenocarcinoma.
news
Machine learning used to predict most effective cancer drugs
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
news
Scientists identify bacterial link with oesophageal cancer
Researchers at NYU Langone Health's Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may directly affect their risk of developing oesophageal cancer.
news
Proton therapy may be better option for patients with esophageal cancer
Proton beam therapy, in combination with chemotherapy, may be a better treatment option than traditional radiation therapy techniques...
news
Combination of conventional drugs enhances tumour cell death
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...
